Abstract 289
Case Summary
A 57-year-old man was diagnosed with locally advanced left nasal malignant melanoma three years ago at another hospital. He had achieved a complete response after receiving heavy particle treatment (57.6 Gy/16 fr) followed by chemotherapy (DAV: dacarbazine, nimustine, vincristine). However, multiple lung metastases were detected by computed tomography (CT) one year ago and he was referred to our hospital. He was treated with four doses of ipilimumab. There was no change in tumor size and he underwent follow-up. He subsequently noticed a swelling of the upper left gingiva at 56 years old. CT revealed multiple metastases in the nasal cavity, maxillary sinus and gingiva, as well as mediastinal lymph node metastasis and progression of the multiple lung metastases. Biopsy of the maxillary sinus showed malignant melanoma. He received seven doses of nivolumab. However, there was local tumor progression and he became anemic due to persistent nasal bleeding. He received palliative radiation (30 Gy/10 fr) for the locally recurrent tumor. Nasal bleeding stopped after radiation and his anemia improved, although there was a mild increase in the size of the lung metastasis. Nivolumab was restarted. Our findings demonstrate that radiation after immunotherapy was effective for controlling nasal malignant melanoma in this patient.
Editorial acknowledgement
Clinical trial identification
Resources from the same session
1006 - Effect On Oxaliplatin-Free Interval For Successful Rechallenge Of Oxaliplatin In Colorectal Cancer Patients Who Had Experienced An Oxaliplatin–Related Hypersensitivity Reaction.
Presenter: Satoshi Horasawa
Session: Poster display - Cocktail
Resources:
Abstract
650 - HGCSG1503 : A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer : Analysis of GERCOR index.
Presenter: Kazuhiro Suzuki
Session: Poster display - Cocktail
Resources:
Abstract
716 - HGCSG1503 : A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer : Analysis of cases of prior regorafenib.
Presenter: Yasushi Tsuji
Session: Poster display - Cocktail
Resources:
Abstract
785 - Efficacy of Ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer.
Presenter: Yosuke Katata
Session: Poster display - Cocktail
Resources:
Abstract
1024 - A China-Manufactured Bevacizumab Biosimilar, HLX04, Matches Avastin® Sourced from China, USA and European Union
Presenter: YanHua Ding
Session: Poster display - Cocktail
Resources:
Abstract
995 - Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer
Presenter: Daisuke Kotani
Session: Poster display - Cocktail
Resources:
Abstract
1072 - Phase Ib/ II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): phase Ib results
Presenter: Yoshinori Kagawa
Session: Poster display - Cocktail
Resources:
Abstract
954 - A pilot case-control study of second or third line treatment with cetuximab-containing chemotherapy (Cetux-chemo) in patients (pts) with metastatic colorectal cancer (mCRC) who were previously treated with Cetux-chemo
Presenter: Cheuk Sang Ho
Session: Poster display - Cocktail
Resources:
Abstract
458 - Real-world evidence of the safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) from Taiwan: A subgroup analysis from the prospective, observational CORRELATE study
Presenter: Kun-Huei Yeh
Session: Poster display - Cocktail
Resources:
Abstract
806 - HGCSG1401 : A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer : Analysis of risk factors for liver dysfunction.
Presenter: Atsushi Ishiguro
Session: Poster display - Cocktail
Resources:
Abstract